Engineering a Scorpion Venom Peptide to Kill Bacteria Better While Being Safer for Human Cells | Research

The takeaway

Single amino acid changes to the scorpion venom peptide Smp24 improved its ability to kill Gram-negative bacteria while reducing toxicity to human cells, creating variants with enhanced therapeutic indices.

Enhanced Therapeutic Indices
Strategic single amino acid substitutions improved the ratio of bacteria-killing to human cell toxicity in scorpion venom peptide Smp24 — making it more selective as a potential antibiotic

What the researchers found

Systematic single amino acid substitutions at the N-terminal, mid-chain, and C-terminal positions of Smp24 revealed position-dependent structure-function relationships:

- **Increased charge (N-, mid-, C-termini)**: Enhanced antimicrobial activity against Gram-negative bacteria across all positions

- **Increased N-terminal hydrophobicity**: Reduced haemolysis and cytotoxicity — a beneficial safety improvement

- **Increased mid-chain hydrophobicity**: Reduced both antimicrobial and cytotoxic activity — a neutral-to-detrimental change

Several modified peptides achieved enhanced therapeutic indices compared to native Smp24, with improved antibacterial selectivity that makes them more promising as potential antibiotic drug candidates.

Why it matters

Antibiotic resistance is one of the greatest threats to global health, and antimicrobial peptides are promising alternatives because bacteria struggle to develop resistance against them. However, off-target toxicity has been the main barrier to clinical development. This study provides a practical engineering roadmap — specific rules about where to modify charge and hydrophobicity — that could be applied to other antimicrobial peptides, not just Smp24, to improve their safety profiles.

How the study worked

Single amino acid substitutions were systematically introduced at N-terminal, mid-chain, and C-terminal positions of the Smp24 peptide. Each variant was tested for antimicrobial activity (minimum inhibitory concentration against Gram-negative bacteria), haemolytic activity (red blood cell lysis), and mammalian cell cytotoxicity. Therapeutic indices were calculated by comparing antimicrobial potency to mammalian toxicity for each variant versus native Smp24.

What this study cannot tell us

All testing was performed in vitro — in vivo pharmacokinetics, biodistribution, and efficacy in animal infection models were not assessed. The therapeutic index improvements, while encouraging, may not be sufficient for clinical use. Peptide stability in biological fluids (serum, digestive enzymes) was not tested. Only single amino acid substitutions were made; combining multiple favorable modifications could produce even better variants but was not explored.

How to read the evidence

This is an in vitro structure-activity relationship study with systematic peptide modifications. While it provides valuable engineering insights and quantitative data on antimicrobial and cytotoxic activity, no in vivo testing was conducted. This represents early-stage preclinical peptide optimization evidence.

When this study was published

Published in 2022, this study contributes to the active field of antimicrobial peptide engineering, where rational design approaches are increasingly being used to optimize natural peptides for therapeutic development.

The bigger picture

Venom-derived peptides are one of the richest sources of antimicrobial compounds in nature, honed by millions of years of evolution. The challenge is converting these natural weapons into safe medicines. This study demonstrates that rational peptide engineering — making targeted amino acid changes based on understanding charge and hydrophobicity — can systematically improve the therapeutic window. These design principles join a growing toolkit for antimicrobial peptide optimization that includes cyclization, stapling, and D-amino acid substitution.

Questions still open

Could combining the most beneficial modifications (increased N-terminal hydrophobicity + increased C-terminal charge) produce a synergistically improved Smp24 variant?
How stable are these modified peptides in blood serum and other biological fluids?
Do the design rules discovered for Smp24 (charge vs hydrophobicity effects by position) apply to other scorpion venom antimicrobial peptides?

Common questions

Can scorpion venom really be used to make antibiotics?

Scorpion venom contains natural antimicrobial peptides that kill bacteria through mechanisms different from conventional antibiotics — they disrupt bacterial membranes, making it very difficult for bacteria to develop resistance. However, these natural peptides also damage human cells. This study shows that by carefully modifying specific amino acids, scientists can keep the bacteria-killing properties while reducing the harm to human cells, making them more viable as future antibiotic drug candidates.

What makes antimicrobial peptides different from regular antibiotics?

Unlike conventional antibiotics that target specific bacterial enzymes or processes (which bacteria can mutate to resist), antimicrobial peptides physically disrupt bacterial cell membranes — something bacteria can't easily evolve away from. They also kill quickly, within minutes rather than hours. The main challenge is that they can also damage human cell membranes, which is why engineering them for selectivity — as this study does — is so important.

Read the original research

Improving the Therapeutic Index of Smp24, a Venom-Derived Antimicrobial Peptide: Increased Activity against Gram-Negative Bacteria.

International journal of molecular sciences, 23(14)

View on PubMed ↗Publisher’s paper ↗

Citation

Rawson, Kirstie M; Lacey, Melissa M; Strong, Peter N; Miller, Keith. (2022). Improving the Therapeutic Index of Smp24, a Venom-Derived Antimicrobial Peptide: Increased Activity against Gram-Negative Bacteria.. International journal of molecular sciences, 23(14). https://doi.org/10.3390/ijms23147979